Trial Profile

Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir/rilpivirine (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacokinetics
Acronyms DRAGON Study
Sponsors ViiV Healthcare

Most Recent Events

19 Sep 2024 Planned End Date changed from 8 Jun 2027 to 3 May 2028.
19 Sep 2024 Planned primary completion date changed from 22 Jul 2025 to 1 Jun 2026.
27 Mar 2024 Planned End Date changed from 13 Jan 2027 to 8 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com